Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$5,619
in 1 filing, $6K under 10b5-1 plans

Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Prener Anne −$6K Director sold 4% of stake
Date Insider Transaction Shares Price Value Owned after
2026-06-04 Seth Alpna Director Sale 10b5-1 −2,625 $10.72 $28K 9,767
2026-06-03 Seth Alpna Director Grant or award +7,142 12,392
2026-06-03 Seth Alpna Director Grant or award · Stock Option (right to buy) +7,433 7,433
2025-06-04 Seth Alpna Director Grant or award +5,250 5,250
2025-06-04 Seth Alpna Director Grant or award · Stock Option (right to buy) +10,500 10,500
2024-05-30 Seth Alpna Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-06-06 Seth Alpna Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-05-01 Seth Alpna Director Grant or award · Stock Option (right to buy) +20,000 20,000

Page 1 of 1 · 8 trades